Intralesional or topical cidofovir (HPMPC, VISTIDE) for the treatment of recurrent genital warts in HIV-1-infected patients.
Orlando
G
G
Fasolo
M M
MM
Beretta
R
R
Signori
R
R
Adriani
B
B
Zanchetta
N
N
Cargnel
A
A
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D000287:Administration, Topical; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000077404:Cidofovir; D003218:Condylomata Acuminata / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D003596:Cytosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004279:DNA, Viral / Q000032:analysis; D006678:HIV / Q000235:genetics; D006801:Humans; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D027383:Papillomaviridae / Q000235:genetics; D030361:Papillomavirus Infections / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D012008:Recurrence; D014412:Tumor Virus Infections / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D019562:Viral Load
D000998:Antiviral Agents; D004279:DNA, Viral; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003596:Cytosine; D000077404:Cidofovir